Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site New Routes to Targeted Therapies

被引：188

作者：

Ross, Jeffrey S. ^{[1
,2
]}

Wang, Kai ^{[1
]}

Gay, Laurie ^{[1
]}

Otto, Geoff A. ^{[1
]}

White, Emily ^{[1
]}

Iwanik, Kiel ^{[1
]}

Palmer, Gary ^{[1
]}

Yelensky, Roman ^{[1
]}

Lipson, Doron M. ^{[1
]}

Chmielecki, Juliann ^{[1
]}

Erlich, Rachel L. ^{[1
]}

Rankin, Andrew N. ^{[1
]}

Ali, Siraj M. ^{[1
]}

Elvin, Julia A. ^{[1
]}

Morosini, Deborah ^{[1
]}

Miller, Vincent A. ^{[1
]}

Stephens, Philip J. ^{[1
]}

机构：

[1] Medicine Inc, Cambridge, MA USA

[2] Albany Med Coll, Dept Pathol & Lab Med, Albany, NY 12208 USA

来源：

JAMA ONCOLOGY | 2015年 / 1卷 / 01期

关键词：

LUNG-CANCER; GENE MUTATION; DIAGNOSIS; ORIGIN; TISSUE; EXPRESSION; AMPLIFICATION; CRIZOTINIB; MANAGEMENT; RECEPTOR;

D O I：

10.1001/jamaoncol.2014.216

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IMPORTANCE For carcinoma of unknown primary site (CUP), determining the primary tumor site may be uninformative and often does not improve outcome. OBJECTIVE To discover opportunities for targeted therapies in patients with CUP not currently searched for in routine practice. DESIGN. SETTING, AND PARTICIPANTS Comprehensive genomic profiling on 200 CUP formalin-fixed paraffin-embedded specimens (mean, 756x coverage) using the hybrid-capture-based FoundationOne assay at academic and community oncology clinics. MAIN OUTCOMES AND MEASURES Presence of targetable genomic alterations (GAs) in CUP and responses to targeted therapies. RESULTS There were 125 adenocarcinomas of unknown primary site (ACUPs) and 75 carcinomas of unknown primary site without features of adenocarcinoma (non-ACUPs). At least 1 GA was found in 192 (96%) of CUP specimens, with a mean (SD) of 4.2 (2.8) GAs per tumor. The most frequent GAs were in TP53 (110 [55%]), KRAS (40 [20%]), CDKN2A (37 [19%]), MYC (23 [12%]), ARID1A (21 [11%]), MCLI (19 [10%]), PIK3CA (17 [9%]), ERBB2 (16 [8%]), PTEN (14 [7%]), EGFR (12 [6%]), SMAD4 (13 [7%]), STKI1 (13 [7%]), SMARCA4 (12 [6%]), RBI (12 [6%]), RICTOR (12 [6%]), MLL2 (12 [6%]), BRAF (11[6 %]), and BRCA2 (11[6 %]). One or more potentially targetable GAs were identified in 169 of 200 (85%) CUP specimens. Mutations or amplifications of ERBB2 were more frequent in ACUPs (13 [10%]) than in non-ACUPs (3 [4%]). Alterations of EGFR (10 [8%] vs 2 [3%]) and BRAF (8 [6%] vs 3 [4%]) were more common in ACUPs than in non-ACUPs. Strikingly, clinically relevant alterations in the receptor tyrosine kinase (RTK)/Ras signaling pathway including alterations in ALK, ARAF, BRAF, EGFR, FGFRI, FGFR2, KIT, KRAS, MAP2K, MET, NF1, NF2, NRAS, RAF1, RET, and ROSI were found in 90 (72%) ACUPs but in only 29 (39%) non-ACUPs (P<. 001). CONCLUSIONS AND RELEVANCE Almost all CUP samples harbored at least 1 clinically relevant GA with potential to influence and personalize therapy. The ACUP tumors were more frequently driven by GAs in the highly druggable RTK/Ras/mitogen-activated protein kinase (MAPK) signaling pathway than the non-ACUP tumors. Comprehensive genomic profiling can identify novel treatment paradigms to address the limited options and poor prognoses of patients with CUR

引用

页码：40 / 49

页数：10

共 61 条

[11] Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing [J].

Frampton, Garrett M. ;

Fichtenholtz, Alex ;

Otto, Geoff A. ;

Wang, Kai ;

Downing, Sean R. ;

He, Jie ;

Schnall-Levin, Michael ;

White, Jared ;

Sanford, Eric M. ;

An, Peter ;

Sun, James ;

Juhn, Frank ;

Brennan, Kristina ;

Iwanik, Kiel ;

Maillet, Ashley ;

Buell, Jamie ;

White, Emily ;

Zhao, Mandy ;

Balasubramanian, Sohail ;

Terzic, Selmira ;

Richards, Tina ;

Banning, Vera ;

Garcia, Lazaro ;

Mahoney, Kristen ;

Zwirko, Zac ;

Donahue, Amy ;

Beltran, Himisha ;

Mosquera, Juan Miguel ;

Rubin, Mark A. ;

Dogan, Snjezana ;

Hedvat, Cyrus V. ;

Berger, Michael F. ;

Pusztai, Lajos ;

Lechner, Matthias ;

Boshoff, Chris ;

Jarosz, Mirna ;

Vietz, Christine ;

Parker, Alex ;

Miller, Vincent A. ;

Ross, Jeffrey S. ;

Curran, John ;

Cronin, Maureen T. ;

Stephens, Philip J. ;

Lipson, Doron ;

Yelensky, Roman .

NATURE BIOTECHNOLOGY, 2013, 31 (11) :1023-+

[12]

Garber K, 2011, JNCI-J NATL CANCER I, V103, DOI 10.1093/jnci/djq556

[13] Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis [J].

Golfinopoulos, Vassilis ;

Pentheroudakis, George ;

Salanti, Georgia ;

Nearchou, Andreas D. ;

Ioannidis, John P. A. ;

Pavlidis, Nicholas .

CANCER TREATMENT REVIEWS, 2009, 35 (07) :570-573

[14] Targeting the p53 Pathway [J].

Golubovskaya, Vita M. ;

Cance, William G. .

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 22 (04) :747-+

[15] Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes [J].

Greco, F. A. ;

Oien, K. ;

Erlander, M. ;

Osborne, R. ;

Varadhachary, G. ;

Bridgewater, J. ;

Cohen, D. ;

Wasan, H. .

ANNALS OF ONCOLOGY, 2012, 23 (02) :298-304

[16]

Greco F A., 2011, Cancer: principles and practice of oncology, V9th, P2033

[17]

Greco FA, 2013, ONCOLOGY-NY, V27, P815

[18] Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology [J].

Greco, F. Anthony ;

Lennington, Wayne J. ;

Spigel, David R. ;

Hainsworth, John D. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (11) :782-790

[19] Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute [J].

Hainsworth, John D. ;

Rubin, Mark S. ;

Spigel, David R. ;

Boccia, Ralph V. ;

Raby, Samuel ;

Quinn, Raven ;

Greco, F. Anthony .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) :217-223

[20] Oxaliplatin and Capecitabine in the Treatment of Patients With Recurrent or Refractory Carcinoma of Unknown Primary Site A Phase 2 Trial of the Sarah Cannon Oncology Research Consortium [J].

Hainsworth, John D. ;

Spigel, David R. ;

Burris, Howard A., III ;

Shipley, Dianna ;

Farley, Cindy ;

Macias-Perez, Ines M. ;

Barton, John ;

Greco, F. Anthony .

CANCER, 2010, 116 (10) :2448-2454

← 1 2 3 4 5 6 7 →